-
Mashup Score: 4Revisiting the PLATO trial - 4 hour(s) ago
A recent BMJ investigation has rekindled the robust debate surrounding the PLATO trial of ticagrelor vs clopidogrel in patients with acute coronary syndromes
Source: cardiologytrials.substack.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Our discussion of "Revisiting the PLATO trial" - 5 hour(s) ago
A review of clinical trials in cardiovascular medicine that have had a major impact on the field. The trials are indexed according to major subject headings and presented in chronological order of publication date.
Source: cardiologytrials.substack.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8
The British Medical Journal has reignited a 14-year debate regarding the antiplatelet drug ticagrelor (Brilianta) and PLATO trial
Source: www.sensible-med.comCategories: General Medicine News, Hem/OncsTweet-
Here is the Controversy as detailed to a broader audience on @Sensible__Med https://t.co/kX0T7sle3B In sum, I don't know how a neutral observer can have confidence in ticagrelor over clopidogrel or prasugrel. I also think this story argues for more robust evidence generation… https://t.co/8tvh6NljYA
-
-
Mashup Score: 4Revisiting the PLATO trial - 5 hour(s) ago
A recent BMJ investigation has rekindled the robust debate surrounding the PLATO trial of ticagrelor vs clopidogrel in patients with acute coronary syndromes
Source: cardiologytrials.substack.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5
For some time, I’ve been an admirer of many of the articles published on Sensible Medicine, a site that usually features articles written by physicians and scientists with diverse opinions on a wide range of biomedical topics.
Source: garyschwitzer.substack.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 14A Strong Critical Appraisal of the CHAGASICS Trial in patients with Chagas Cardiomyopathy - 7 day(s) ago
Dr. Anis Rassi Jr helped design this trial. He ended up resigning authorship due to flaws in trial conduct and reporting. JAMA-Cardiology refused to publish his concerns.
Source: www.sensible-med.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Review of the PREVENT trial - 19 day(s) ago
PCI versus medical therapy alone for vulnerable coronary plaques
Source: cardiologytrials.substack.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 21
Adherence to medications that are prescribed after myocardial infarction is poor. Eliminating out-of-pocket costs may increase adherence and improve outcomes. We enrolled patients discharged after …
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
Background There is common belief among some medical researchers that if a potential surrogate endpoint is highly correlated with a true endpoint, then a positive (or negative) difference in potential surrogate endpoints between randomization groups would imply a positive (or negative) difference in unobserved true endpoints between randomization groups. We investigate this belief when the potential surrogate and unobserved true endpoints are perfectly correlated within each randomization group. Methods We use a graphical approach. The vertical axis is the unobserved true endpoint and the horizontal axis is the potential surrogate endpoint. Perfect correlation within each randomization group implies that, for each randomization group, potential surrogate and true endpoints are related by a straight line. In this scenario the investigator does not know the slopes or intercepts. We consider a plausible example where the slope of the line is higher for the experimental group than for the
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 65A Story about Surrogate Outcomes - 21 day(s) ago
I was part of a big meta-analysis of heart failure trials looking at how we measure clinical outcomes. We have more to come on this topic.
Source: www.sensible-med.comCategories: General Medicine News, Hem/OncsTweet
Here is our revision over at @CVtrials with @AndrewFoy82 @MRuzieh https://t.co/KAr6mg9cDq We missed the controversy on our first run through. BTW -- you should consider subscribing to the Cardiology Trials Substack as we are chronicling all of the seminal trials in cardiology